# A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

> **NCT06246110** · PHASE2 · RECRUITING · sponsor: **Eikon Therapeutics** · enrollment: 70 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** EIK1001
- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06246110
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246110, "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06246110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*